NBIO OTC
Nascent Biotech, Inc.
1W: +0.0%
1M: -33.3%
3M: -60.0%
YTD: -66.7%
1Y: -97.1%
3Y: -99.7%
5Y: -99.8%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$320K
+0.0% ▲
Operating Income
-$2M
-3.4% ▼
Net Income
-$2M
+25.5% ▲
EPS (Diluted)
$-0.01
+43.2% ▲
EBITDA
$527K
+149.2% ▲
5Y CAGR: +563.6%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $750K | $1M | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +33.3% | -100.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $320K |
| Gross Profit | $0 | $750K | $1M | $0 | -$320K |
| Gross Margin | — | 100.0% | 100.0% | — | — |
| R&D Expenses | $294K | $322K | $197K | $654K | $203K |
| SG&A Expenses | $3M | $2M | $927K | $2M | $2M |
| Operating Expenses | $3M | $2M | $1M | $2M | $2M |
| Operating Income | -$3M | -$1M | -$457K | -$2M | -$2M |
| Operating Margin | — | -186.7% | -45.7% | — | — |
| Interest Expense | $87K | $356K | $487K | $2M | $385K |
| Income Before Tax | -$4M | -$959K | -$470K | -$3M | -$2M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$4M | -$959K | -$470K | -$3M | -$2M |
| Net Margin | — | -127.9% | -47.0% | — | — |
| EPS (Diluted) | $-0.12 | $-0.01 | $-0.00 | $-0.02 | $-0.01 |
| EBITDA | -$470K | -$603K | $17K | -$1M | $527K |
| Shares Outstanding | 34M | 72M | 108M | 119M | 156M |